Risk Factors Update Summary

• Accumulated deficit increased from $577 million to $679 million, a significant change.
• Plaintiffs increasingly bring privacy-related claims, including mass arbitration demands, with potential monumental statutory damages.
• Cash and cash equivalents and marketable securities increased from $100 million to $141 million.
• Loss of New Technology APC may restrict Medicare access to Jelmyto, impacting revenue.
• Remaining capacity under the ATM Sales Agreement decreased from $83.4 million to $56.8 million.
• CMS may reassign service to appropriate APC based on claims data, affecting reimbursement levels.
• Term Loans increased from $100 million to $125 million, with additional tranches planned.
• Hamas conflict initiated state of war, posing risks of larger conflict and economic implications.
• Sales agreement with Cowen allows for offering and selling ordinary shares up to $100 million.
• Military reserve duty call-ups may lead to labor shortage, impacting operations and liquidity.
• Entered into a loan agreement with Pharmakon Advisors for an aggregate principal amount of up to $100 million.
• Adverse financial industry developments could affect business operations and financial condition.
• Received a Paragraph IV Certification Notice Letter from Teva Pharmaceuticals regarding a generic version of Jelmyto.
• Market volatility and disruptions may impact stock price and require operational delays.